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Objective: The purpose of this study is to determine if there are any acoustic variables 
that can determine compromised lung function in patients with asthma and COPD. 
Methods: This study involved using mobile and wearable technology to record voice and 
respiratory changes during various speaking and breathing tasks before and after 
administration of albuterol. Collaborators at Samsung Research America, Inc. used 
algorithms to measure pause time, pause frequency, respiratory rate, and inhale:exhale 
ratio. These variables were correlated with spirometry values before and after albuterol to 
assess clinical significance.  Results:  We identified several acoustic markers that 
significantly correlate with lung function in patients with asthma and COPD.  In 
particular, we found that the ratio of the one-second forced expiratory volume to forced 
vital capacity (FEV1/FVC) after administration of albuterol significantly correlated with 
the inhale:exhale ratio in asthma patients during the tidal breathing task. The post-
albuterol FEV1/FVC significantly correlated with the inhale:exhale ratio in COPD 
patients during the supine breathing task. The pre-albuterol FVC significantly correlated 
with the pause frequency in asthma patients during the scripted speech task.  Conclusion: 
The results in this study indicate that pause frequency and inhale:exhale ratio may be 
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important biomarkers for identifying a respiratory illness, such as asthma and COPD. 
More research needs to be done using digital health to monitor disease symptoms with a 
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Asthma and chronic obstructive pulmonary disease (COPD) are two types of 
chronic inflammatory respiratory diseases commonly seen by physicians that 
significantly impact the daily lives of patients, financially and in some cases fatally. This 
paper attempts to present a novel procedure that can aid in monitoring the 
pathophysiology of asthma and COPD by comparing voice analytics to pulmonary 
function tests.  
PATHOLOGY OF ASTHMA 
Asthma is a type of chronic inflammatory respiratory disease characterized by 
airway hyper-responsiveness and reversible airflow obstruction that is found in children 
as well as adults. Asthmatics suffer from inflammation of the airways triggered by certain 
stimuli in the environment that lead to narrowing of the airways. A widely recognized 
biomarker for inflammation is the level of eosinophils in the blood or sputum.39 In the 
setting of increased airway inflammation, asthmatic patients may present with high blood 
eosinophil counts and have a profound response to medications that relax airway smooth 
muscles, called bronchodilators, such as albuterol. In the setting of greater inflammation, 
and thus higher eosinophil count, the response to bronchodilators may be even greater.8 
Additionally, patients with higher blood eosinophil counts are at a higher risk for asthma 
exacerbations.18 Patients typically present with any of the following symptoms: 
wheezing, short of breath, chest tightness, and cough. Worsening of these symptoms can 
impede the patient’s overall ability to breathe, which is called an asthma exacerbation or 
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asthma attack. Risk factors that can predispose a patient to asthma are allergies, obesity, 
smoking, pollution and poverty.32 
PATHOLOGY OF COPD 
COPD is a progressive inflammatory disease of the airways with irreversible 
limitation of airflow found in adults primarily. This is due to the progressive loss of 
elastic recoil and remodeling of the airways. In a spirometry test, this can be illustrated 
by a progressive decline in the forced expiratory volume in one second (FEV1) over time. 
Loss of lung elastic recoil and airway narrowing cause inadequate lung emptying with 
greater difficulty as the disease progresses. Patients with COPD typically present with 
shortness of breath, cough, and sputum production.  COPD exacerbations, which are 
episodes of worsening respiratory symptoms, including shortness of breath and increased 
cough and sputum volume, are slower to resolve with medications as compared to 
asthma.  Often, COPD exacerbations may require treatment with antibiotics in addition to 
bronchodilators and corticosteroids.11 It is very common for COPD patients to have a 
history of tobacco smoking. Other risks factors for COPD are second-hand smoke, poor 
air quality and increased particulate matter in the environment, household, or occupation.  
DISEASE PREVALENCE 
 According to World Health Organization (WHO) there are approximately 235 
million people around the world that suffer from asthma.32 According to the 2015 Global 
Burden of Disease (GBD) study, asthma was the most prevalent chronic airways disease 
worldwide in 2015.37  In the same study, it was estimated that about 3 million people died 
from COPD or COPD related complications worldwide, which was an 11.6% increase 
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compared to 1990.37 According to the World Health Organization, by 2030, COPD will 
be the third leading cause of death in the world.37 In the United States alone, COPD was 
ranked number five in top ten causes of death, ranked fourth in years of life lost from 
premature death, ranked sixth in years lived with disability, and ranked second in 
disability-adjusted life-years.23  
DISEASE BURDEN 
COPD and asthma ranked in the top twenty conditions causing disability 
globally.37 The medical burden of COPD and asthma, including cough, wheeze, and short 
of breath, can result in an inability to keep up with peers and in turn poses a risk for 
attacks of severe shortness of breath. These patients struggle daily with significant 
economic and social burden. This is largely due to the fact that exacerbations of both 
asthma and COPD can require immediate medical attention at home by increasing 
medication or requiring an emergency department visit or hospitalization. Both types of 
exacerbations might require non-invasive positive-pressure ventilation (NIPPV), oxygen 
therapy, intubation, or an increase in medication but the cost of an emergency department 
visit alone can be detrimental to these patients. In the United States, there are about two 
million emergency room visits a year for asthma exacerbations alone.38 Additionally, 
COPD, accounts for about fifty billion dollars of the US health care budget annually.9 
COPD and asthma can also have a social strain on patients’ lives by causing awakening 
during sleep, keeping the patient from doing tasks at work, school or at home, and having 
limitations to activities and exertion.   
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Interestingly, disease presentations and morbidity are variable in asthmatics and 
patients with COPD, therefore not all patients suffer with the same economic and social 
strains.  Some patients may appear stable throughout their entire life, while others suffer 
from frequent and severe exacerbations. Patients who are repeatedly admitted to a 
hospital for an asthma or COPD exacerbation show instability of the disease and require 
greater management control. A greater understanding of disease variability will benefit 
physicians and patients worldwide. Biomarkers that can help distinguish between patients 
who are more controlled or nearly asymptomatic with little to no lung function decline 
and uncontrolled patients with frequent exacerbations will aid in accurate prognosis and 
disease management. 
DIAGNOSTIC TESTING 
It is important to distinguish between asthma and COPD and those controlled and 
uncontrolled for a better understanding of a patient’s prognosis. Currently, in order to 
understand the severity of the diseases a patient requires pulmonary function tests. 
Additionally, disease-specific questionnaires can also subjectively determine control of 
disease, but lack objective measurement. 
Spirometry is a type of pulmonary function test (PFT) that is fundamental in 
assessment of general airway health. It measures the volume of air a patient can inhale 
and exhale with maximum effort. Specifically, spirometry measures the forced volume 
capacity (FVC), which is the volume of air that gets released during complete exhalation 
(from a full breath in to complete emptying of air from the lungs); forced expiratory 
volume in one second (FEV1), which is the volume of air that gets released as forcefully 
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and completely as possible in the first second; and the ratio between the two 
(FEV1/FVC). 29 It is most commonly used in the assessment of lung function as well as 
monitoring lung health, therefore it is not uncommon that patients have repeat spirometry 
throughout their lifetime.  
Spirometry has also been demonstrated to determine airflow defects, suggesting 
specific disease states and severity.  For example, Asthma can be suggested if the patient 
shows variability in FEV1 across multiple past spirometry results. FEV1 variability is 
shown when the change in FEV1 between any two past spirometry values is greater than 
15%.29 COPD is suggested if the patient has a persistent reduced FEV1/FVC even after 
administration of a bronchodilator in the right clinical context, usually a smoking history. 
Additionally, the American Thoracic Society (ATS) defines severity of an abnormal 
pulmonary function test using FEV1 percent predicted, in five categories: mild (FEV1 % 
predicted >70), moderate (FEV1 % predicted 60-69), moderately severe (FEV1 % 
predicted 50-59), severe (FEV1 % predicted 35-49) and very severe (FEV1 % predicted 
<35). 29 
A bronchodilator test is another type of pulmonary function test that can be 
performed to assess the reversibility of airflow obstruction. In this test, spirometry is 
repeated after administration of a bronchodilator medication, such as albuterol, and the 
changes in FEV1, FVC, and FEV1/FVC are measured. The American Thoracic Society 
defines a significant or positive bronchodilator response as a greater than 12% increase 
and 200 mL in FEV1 or FVC in an individual patient from baseline after administration 
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of medication.29 A positive bronchodilator response would suggest that the patient has 
reversible airflow obstruction.  
Assessment of reversibility in airflow obstruction by a bronchodilator test can 
help diagnose and evaluate disease. For example, Asthma can be suggested if a patient 
presenting with asthma-like symptoms has a positive bronchodilator response. Since 
reversibility is a key feature of asthma and not typically COPD, it might be able to aid in 
the differentiation between the two diseases.  However, it is also possible that patients 
with COPD can have a bronchodilator response. Although, the ATS defines a diagnosis 
of COPD if a patient presenting with COPD-like symptoms has an airflow obstruction 
with a post-bronchodilator FEV1/FVC ratio < 0.7.29  Patients with reversible airflow 
obstruction have significant alleviation with treatment and a decrease in morbidity; these 
patients have a better prognosis than patients with fixed obstruction.29 
A methacholine challenge test (MCT) is another type of pulmonary function test 
performed on patients that illustrate airway a hyper-reactivity, a key feature of asthma, 
but show otherwise unexplained symptoms of cough, wheezing, chest tightness and/or 
dyspnea. Bronchoconstriction is medically induced with increasing doses of 
methacholine (0.063 mg/ml, 0.250 mg/ml, 1.00 mg/ml, 4.000 mg/ml, 16,000 mg/ml). The 
patient undergoes a spirometry test at baseline and after administration of a saline 
solution. The spirometry test is repeated after each consecutive dose of methacholine. A 
positive MCT is defined by a greater than or equal to a 20% decline in FEV1 from 
baseline after any of the five doses, demonstrating airway hyper-responsiveness, 
confirming asthma. After the exam the patient is immediately administered a 
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bronchodilator. A spirometry is done after the bronchodilator to confirm that the patient 
has recovered. A positive MCT could confirm a diagnosis of asthma when other tests are 
ambiguous.  
Correlations between PFT values and clinical presentation may aid in 
distinguishing COPD from asthma. However, there are several limitations to the 
aforementioned PFTs in which the physician might need to interpret results with caution. 
For example, spirometry is often influenced by subjective measures since results are 
based on patient effort. It is critical that the patient’s inspiration and expiration efforts are 
done to the best of their ability; otherwise, lung function values will be lower than usual. 
These poor effort values could be misinterpreted as obstruction and/or restriction deficits. 
The respiratory technician reports whether the patient used maximal effort throughout the 
exam. Additionally, the patient’s height, age, sex, and race all have an effect on 
spirometry values. Therefore, the machine calculates predicted (reference) values based 
on healthy subjects with the same sex, age, height, and racial characteristics as the patient 
being tested.29 Physicians then compare the patient’s values to the predicated normal 
values, which were based on demographics, for lung health assessment. Often, the 
technicians rely on the patient’s self reported height or weight, which might not be 
accurate and may affect their reference values.  
This ambiguity around diagnosis exemplifies the need to establish another test 
that is efficient at differentiating between the two chronic pulmonary diseases. Physicians 
face many challenges in distinguishing patients with COPD from asthmatics because they 
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can present with clinical and biological similarities, in addition to overlapping spirometry 
outcomes.  
ASTHMA-COPD OVERLAP SYNDROME 
Asthma and COPD share similar symptoms, risk factors, and exacerbation 
triggers such as viruses, bacteria, allergens, pollutants and fumes. Additionally, it is not 
uncommon to find that patients present with phenotypes of both inflammatory diseases. 
In fact, in the past decade patients who present with features of both asthma and COPD 
have been newly diagnosed with Asthma-COPD overlap syndrome (ACOS).  
In ACOS, the typical overlapping characteristics are inflammation, or atopy, and 
obstruction of the airway with the reversibility and evidence of a progressive disease.8 
For example, an ACOS patient might have a physician’s diagnosis of COPD based on a 
prior spirometry test showing significant airflow obstruction and having a smoking 
history but also show variable airflow obstruction over time or a positive bronchodilator 
response based on a bronchodilator test and a high eosinophil count, which would also be 
significant evidence for a physician’s diagnosis of asthma. This patient might present 
with episodic wheezing and/or dyspnea and possibly poorer prognosis than COPD alone. 
It is important for physicians to recognize ACOS patients since these patients would 
benefit from therapies for asthma, such as inhaled corticosteroids, more than a patient 
presenting with COPD alone. 
There are currently no specific clinical, inflammatory or physiological features 
specific in diagnosing ACOS making it more challenging for physicians to demonstrate 
consistency in diagnoses and the prevalence. In this paper, ACOS is defined as patients 
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who have a physician’s diagnosis of asthma and COPD, who have a history of wheezing 
and dyspnea, who have an FEV1/FVC < 70% and have obtained prior testing showing 
one of the following test results: variable airflow obstruction over time indicated by an 
FEV1 change by ≥ 15% observed on two or more measurements, or a positive 
bronchodilator response indicated by an FEV1 increase by ≥ 15% or a positive 
Methacholine Challenge Test indicated by in a 20% decline in FEV1 from baseline.  
TREATMENTS 
It is important to distinguish the differences between chronic inflammatory 
pulmonary diseases because symptom management is critical. A more efficient diagnosis 
can lead to an early avoidance of risk factors and irritants such as smoke exposure, 
occupational exposures, and weight gain. Taking early appropriate action may help slow 
down lung function decline and decrease the frequency of exacerbations, keeping 
symptoms under control. Poorly controlled asthma or COPD can result in a high rate of 
morbidity and mortality and in turn result in an increased financial burden.  
It is crucial to have an accurate diagnosis of asthma or COPD not only so that 
patients can recognize their own disease state and make appropriate life choices in an 
attempt to decrease exacerbations and symptoms, but also so that the provider can 
determine the optimal choice of treatment and plan for symptom management.  
Introduction of inhaled corticosteroids, such as fluticasone or budesonide, in 
addition to beta agonists help improve asthma control by decreasing airway inflammation 
and exacerbation frequency.  For stable COPD patients with respiratory symptoms and 
FEV1 <60% predicted, the American Thoracic Society (ATS) strongly suggests 
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monotherapy with an inhaled bronchodilator, a long-acting inhaled anti-cholinergic or 
long-acting inhaled beta-agonist.31 Additionally, ATS strongly suggest continuous 
supplemental oxygen therapy in patients with COPD who have severe hypoxemia.31 
Patients who present with both asthma and COPD are treated with a combination of 
inhaled corticosteroids, inhaled long-acting beta-2 agonists (LABA), and long-acting 
muscarinic antagonists (LAMA).32 Appropriate treatment following correct diagnosis 
produces long-lasting impactful effects on patients by helping them control symptoms 
while improving quality of life.   
SPECIFIC AIMS 
The effects of asthma and COPD, such as dyspnea, can cause significant and 
noticeable changes in speaking.15 Speech is made up of deep inhalations prior to speech 
followed by a continuous exhalation during vocalization.  It can be suggested that speech 
requires a greater effort in respiration than breathing at rest. Therefore, it is likely that 
patients with respiratory illnesses, such as chronic inflammation or airway obstruction 
seen in COPD and asthma, would have a significant change in speech due to the impaired 
expiratory airflow. Many studies have shown that patients with asthma have distinct 
vocal characteristics that differentiate them from individuals without asthma.15 It can be 
hypothesized that when lung function is compromised, acoustic variables can differ from 
the norm. This paper investigates how acoustic variables (pause time, pause frequency, 
respiration rate, and inhale exhale ratio) are related to the compromised pulmonary 




Additionally, complexity and variability between asthma, COPD, and ACOS and 
the imperfect tools to accurately distinguish between the diseases challenge us to develop 
new diagnostic tools. There is a need for new tools that can provide an immediate and 
accurate diagnosis of airflow obstruction and phenotype the type of disease.  This paper 
uses acoustic variables (pause time, pause frequency, respiration rate, and inhale exhale 
ratio) and clinical data (spirometry values and eosinophil count) as biomarkers to 
characterize patients with asthma and COPD. 
This tool may significantly improve the quality of life for patients with asthma 
and COPD and better understand the disease management. This paper also aims to 
promote research in both asthma and COPD and guide future research in using wearable 












This prospective cohort study investigated novel biomarkers to characterize 
patients with compromised pulmonary function, such as in asthma and COPD by 
analyzing acoustic variables (pause time, pause frequency, respiration rate, and inhale 
exhale ratio) and clinical data (spirometry values and eosinophil count).	
The primary outcome was to investigate how acoustic variables (pause time, 
pause frequency, respiration rate, and inhale exhale ratio) are related to the compromised 
pulmonary function as told by hospital-administered spirometry. The secondary outcome 
was to see if the acoustic variables (pause time, pause frequency, respiration rate, and 
inhale exhale ratio), along with the clinical data (spirometry values and eosinophil count) 
can serve as biomarkers to characterize patients with asthma and patients with COPD.  
Pause Time is the average duration of pauses for breath between speech segments, 
and Pause Frequency is the estimated number of pauses per minute, based on frequency 
of occurrence of pauses in that task. Respiratory Rate is the rate at which breathing 
occurs measured in breaths per minute using a phone motion sensor. The ratio between 
time inhale to time exhale demonstrates a breathing pattern computed from the phone 
motion sensor data. It can be suggested that patients with respiratory illnesses, such as 
chronic inflammation or airway obstruction seen in asthma and COPD, would have a 
significant change in speech and respiration due to the irregular airflow. Therefore it is 
hypothesized that acoustic variables can demonstrate compromised pulmonary function 
seen in asthma and COPD, as told in a hospital administered spirometry test.  
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This study obtained approval by the Institutional Review Board prior to human 
subject enrollment at Brigham and Women’s Hospital. The data analyzed was collected 
at subject visit and from their medical record, via a hospital system called EPIC. 
SUBJECT SELECTION 
Fifty-six English speaking adult patients with a history of asthma or COPD from 
the pulmonary clinic at the Brigham and Women’s Hospital were recruited for this study. 
The subjects had to be fluent in English since the algorithm used by Samsung Research 
America, Inc. for voice analysis is only currently available for English. The diagnosis of 
asthma was determined by a physician’s diagnosis of asthma, a history of wheezing 
and/or difficulty breathing, and one of the following observed outcomes: variable airflow 
obstruction over time, defined as a change in FEV1 greater or equal to 15% on two or 
more measurements, or a positive bronchodilator response, defined as a FEV1 increase 
by greater or equal to 15%, or documentation of a positive Methacholine Challenge Test, 
defined by a 20% decline in FEV1 from baseline. The diagnosis of COPD was 
determined by a physician’s diagnosis of COPD, a history of difficulty breathing and a 
FEV1/FVC less than 70% (Figure 1).  
Patients who received any other diagnosis of pulmonary diseases, those who have 
congestive heart failure as diagnosed by the New York Association (NYHA) Class II or 
greater symptoms, who have undergone a pneumonectomy or laryngeal surgery, who 
have vocal cord dysfunction, who have a known intolerance or allergy to bronchodilators, 
or are pregnant were excluded. The decision to exclude women who were pregnant was 
decided to prevent any risk that may occur for the mother or fetus with exposure to 
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repeated spirometry, bronchodilators, or wearable technology. In the Asthma cohort, any 
subjects with a greater than 20 pack-year history of smoking were also excluded (Figure 
1). This was added into the exclusion criteria to eliminate the possibility of other lung 
diseases, rather than just pure asthma.  
 
Figure 1. Subject Selection for Study Protocol. A checkmark indicates inclusion 
criteria; a minus sign indicates exclusion criteria. VCD = Vocal Cord Disorder.  
 
STUDY PROCEDURE 
Potentially eligible subjects who agreed to participate were asked to come into the 
Brigham and Women’s Hospital to undergo a two-hour study visit. At the beginning of 
the study visit, the patients met with a research assistant to determine eligibility in the 
study followed by the patient providing written informed consent. If the patient was 
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determined eligible and responded in the affirmative, then baseline data for each subject 
were taken from the initial visit encounter, including demographics, date of birth, age, 
race, sex, smoking status and vital signs.  Additionally, the subject underwent various 
study procedures using several devices, including two smart phones, a smart watch, and a 
chestband.  
These aforementioned devices recorded throughout the visit collecting data about 
respirations, heart rate, oxygen saturation, as well as acoustic recordings to record any 
coughs, sneezing, sneezes, throat clears, and other sounds related to respiratory 
symptoms. The Bioharness, or chestband, is a physiological monitoring device that 
consists of a strap that goes around the chest with an electronic monitor that attaches to 
the strap to store and transmit the data collected from the subject, including heart rate, 
respiratory rate, and motion. Vital signs were obtain at the beginning of the study, 
including heart rate, blood pressure, height, weight, and transcutaneous oxygen 
saturation. Then, several standardized questionnaires related to respiratory symptoms 
were administered.  
The BioHarness strap was placed around the participant’s chest. The participants 
were instructed to put one phone in their pocket or a fanny pack that went around the 
waist. The participants were instructed to hold the second smart phone in their hand and 
keep it at arms distance at all times. The smart watch was placed on the patient’s wrist. 
The research assistant (RA) used an RA dedicated smart phone that presented the 
stepwise protocol tasks and allowed the RA to manually annotate any respiratory noises.  
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The participants underwent a series of breathing tasks and maneuvers, after the device 
placement and initiation of device recording.  
The first standardized maneuver was tidal breathing for 1 minute. The participants 
were instructed to hold the arm with the watch over their abdomen and with the opposite 
hand, hold the phone over their chest. The research assistant then asked the participants to 
breathe normally while counting the number of breaths silently in their head when 
instructed to ‘start’. At the end of one minute, the RA noted the number of breaths 
according to the subject count into the RA phone.  
The second standardized maneuver was supine breathing for 1 minute. Still 
holding the same position with the phone over the chest, finger on the red light, and 
watch over the abdomen, the participants underwent a similar task from the first except 
lying down at least at a 45-degree angle. Again, the participants were asked to breathe 
normally and count the number of breaths in their end. At the end of the session the 
subjects were asked how many breaths they counted and the RA made note of the number 
in the RA smartphone.  
The third standardized maneuver was the spontaneous speech task for one minute. 
In this session the participants held the hand phone anywhere within arm’s reach, while 
speaking continuously about any topic of his or her own choosing. The RA could also 
prompt the participants with a topic. Alternatively, in the fourth task, the subject was 
asked to read aloud a standard passage for one minute.  
The fifth task was a bronchodilator responsiveness test during spirometry 
performed by a certified respiratory technician. Spirometry measurements were obtained 
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at baseline, before administration of a bronchodilator. During this exam, the participants 
were asked by the technician to breathe normally, then to take a deep inhale from the 
mouthpiece, followed by a quick expiration with an intention to exhale all the air out of 
their lungs. After the technician determined the quality of the exam as appropriate, a 
bronchodilator (2.5 mg of albuterol sulfate, nebulized) was administered. The spirometry 
was repeated after the bronchodilator.   
The spirometry values measured, included forced Vital Capacity (FVC), Forced 
Expiratory volume in one second (FEV1) and the ratio between the two (FVC/FEV1). A 
bronchodilator response test was done and recorded as a positive or negative 
bronchodilator response. Subjects who had a significant bronchodilator response were 
denoted as positive because they met the ATS guidelines defined as having a greater than 
12% increase and 200 mL in FEV1 and/or FVC in an individual subject from baseline 
after administration of albuterol.  
Following the hospital spirometry, the participants repeated task 1, tidal 
breathing, task 2, supine breathing, and task 4, scripted speech session. The study visit 
was determined as complete at the end of the second round of standardized assessments. 
After the study visit was complete, the devices were connected to the study 
computer and the data was immediately extracted from the study devices using a python 
script. The data was then uploaded to a secure server shared with our collaborators at 
Samsung Research America, Inc. Their team ran their voice analytic algorithms on the 
data to produce acoustic and respiratory annotations, such as, pause time, pause 
frequency, respiration rate, and inhale exhale ratio. The SRA study engineers assessed the 
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respiration rate and the inhale exhale ratio by using the phone motion sensor data, the 
accelerometer and gyroscope data, collected from the positioning of the phone and watch 
across the body in tasks one and two. The chestband and the breath count were not used 
in this analysis rather served to compare and determine accuracy of the respiration rate 
data using the phone and watch. 
 
Figure 2.  Workflow For The Protocol’s Standardized Maneuvers. “Standardized 
procedures I” indicates the tasks done prior to albuterol. “Standardized procedures II” 
indicates the tasks done after inhalation of albuterol. 
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STATISTICAL ANALYSIS  
The acoustic and respiratory annotations were correlated with the physiological 
clinical data, blood eosinophil counts and spirometry values, pre and post albuterol. The 
subjects highest noted levels recorded in their medical chart were extracted from the 
patient medical record, EPIC.  
A Pearson’s R correlation was performed between the clinical data (spirometry 
values and eosinophil count) and the acoustic variables (pause time, pause frequency, 
respiration rate, and inhale exhale ratio). A welch t-test was conducted in R program to 
measure the differences of means between the asthmatic cohort and the COPD cohort. All 







 Fifty-six English speaking adult patients with a history of asthma or COPD from 
the pulmonary clinic at BWH were recruited, of which 20 were male and 36 were female. 
In the cohorts there were 26 asthmatics and 30 subjects with COPD (Table 1). The most 
common races in the sample were White American (about 79%) and Black or African 
American (about 18%). The average age of subjects with asthma was 53 years old and the 
average age of subjects with COPD was 66 years of age. Twenty-two of the twenty-six 
asthmatics indicated as never smokers (85%), while four of the twenty-six asthmatics 
indicated they were previous smokers (15%). Alternatively, of the thirty subjects with 
COPD, one indicated never smoked (3%), twenty-five were previous smokers (83%), 
while four were current smokers (13%).  
The disease severity of both asthmatics and subjects with COPD is shown in 
Table 1. Amongst the asthmatics, the disease severity was 42%, 23%, 12%, 8% and 15% 
for mild, moderate, moderately severe, severe and very severe cases, respectively. Of 
those with COPD, the disease severity was 23%, 10%, 23%, 20%, and 17% for mild, 







Table 1. Demographics, Social and Clinical Characteristics of Study Participants 
According to Disease, Asthma or COPD. Mild  = FEV1 % predicted >70; moderate = 
FEV1 % predicted 60-69; moderately severe = FEV1 % predicted 50-59; severe = FEV1 
% predicted 35-49; very severe = FEV1 % predicted <35. 
 




Sex   
Male 9 11 
Female 17 19 
Age   
Mean 53 66 
Median 58 66 
Min 21 51 
Max 76 80 
BMI   
Mean 31.25 29.4 
Median 30.63 30.19 
Min 21.43 22.12 
Max 49.09 43.42 
Race    
White American 18 26 
Black or African American 6 4 
 Asian American 1 0 
Some other race 1 0 
Unavailable/Unknown 1 0 
Smoking Status   
Never Smoker 22 1 
Previous Smoker (QUIT) 4 25 
Current Smoker 0 4 
Disease Severity    
Mild 11 7 
Moderate 6 3 
Moderately Severe 3 7 
Severe 2 6 
Very Severe 4 5 
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During inflammation, as seen in these chronic inflammatory diseases, the number 
of circulating eosinophils typically increases. Normal ranges of eosinophils in the blood 
lie below 450 cells/uL (0.45K/uL) and 5% of differential (Kovalszki_2016). In Table 2, 
across nearly all asthmatic severities, the absolute eosinophil counts were high (>0.450 
K/uL). Amongst the asthmatics, elevated absolute eosinophil values were 45%, 67%, 0%, 
50% and 50% for those with mild, moderate, moderately severe, severe, and very severe 
cases, respectively. Overall, the average absolute eosinophil count was high across all 
asthmatics.  
 
Table 2. Summary Hematological Blood Differential Laboratory Results Showing 
Highest Recorded Eosinophil In Medical Record By Disease Severity For Asthma 
Patients. Mild  = FEV1 % predicted >70; moderate = FEV1 % predicted 60-69; 
moderately severe = FEV1 % predicted 50-59; severe = FEV1 % predicted 35-49; very 










Mild (n= 11) 0.50 5.75 
Moderate (n=6) 0.66 7.3 
Moderately Severe (n=3) 0.26 3.4 
Severe (n=2) 0.48 4.45 
Very Severe (n=4) 1.04 8.85 









Table 3. Summary Hematological Blood Differential Laboratory Results Showing 
Highest Recorded Eosinophil In Medical Record By Disease Severity For COPD 
Patients. Mild  = FEV1 % predicted >70; moderate = FEV1 % predicted 60-69; 
moderately severe = FEV1 % predicted 50-59; severe = FEV1 % predicted 35-49; very 









 (%)  
Mild (n=7) 0.38 5.45 
Moderate (n=3) 0.31 3.33 
Moderately Severe (n=7) 0.54 6.97 
Severe (n=6) 0.75 7.94 
Very Severe (n=5) 0.42 3.62 
Total 0.416 3.62 
 
 
Amongst subjects with COPD, across all severities, the average absolute 
eosinophil was in the normal range. However, there were a handful of COPD subjects 
with high absolute eosinophil values, including 43% with mild COPD, 33% with 
moderate COPD, 14% with moderately severe COPD, and 43% with severe COPD. 
A summary of spirometry values is shown in Table 3. Subjects who had a 
significant bronchodilator response indicates that they met the ATS guidelines defined as 
having a change greater than a 12% and 200 mL increase in FEV1 and/or FVC in an 
individual subject from baseline after administration of albuterol.  
Eleven asthmatics had a significant bronchodilator response (42%). Nine subjects 
with COPD had a bronchodilator response (30%). The average change in FEV1 in 
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asthmatics was 0.16 L; the average change in FVC in asthmatics was 0.23 L. The average 
change in FEV1 in subjects with COPD was 0.12 L; the average change in FVC in 
subjects with COPD was 0.21 L. 
 
Table 4. A Summary Of The Pulmonary Function Test From All Study 
Participants. The percent predicted values were generated by the spirometry machine 
using algorithms based on the patient’s demographics and how a healthy control would 
preform with similar demographics. ‘Pre-‘ indicates before administration of albuterol; 
‘Post-‘ indicates after administration of albuterol. FEV1 = forced expiratory volume in 






PFT    
Pre-FEV1 (Liters) 1.82 1.38 
Pre-FEV1 (% predicted) 68.52 53.9 
Post-FEV1 (Liters) 1.98 1.47 
Post-FEV1 (% predicted) 68.52 57.44 
Pre-FVC (Liters) 2.79 2.57 
Pre-FVC (% predicted) 82.16 77.45 
Post-FVC (Liters) 3.01 2.75 
Post-FVC (% Predicted) 77.81 82.84 
Pre-FEV1/FVC (Liters) 64.81 54.14 
Post-FEV1/FVC (Liters) 66.64 53.64 
Change in FEV1 (Liters) 0.16 0.12 
Change in FVC (Liters) 0.23 0.21 
 Positive BDR 11 9 
 
The acoustic variables used included pause time and pause frequency in speech 
tasks, as well as the inhale exhale ratio and respiratory rate in breathing tasks. The 
variables were correlated with the clinical values including, blood eosinophil count and 
spirometry values to assess the strength of a linear relationship between the paired data.  
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When the clinical values from the asthma cohort were correlated with the acoustic 
variables from the asthma cohort, the following two significant relationships were 
observed: the asthmatic post-FEV1/FVC values with the average asthmatic inhale exhale 
ratio during tidal breathing post albuterol, (r = -0.46, p = 0.03), as well as the asthmatic 
pre-FVC values with the asthmatic Pause Frequency values during the Scripted Speech 
task before albuterol, (r = -0.39, p = 0.05). 
When the clinical values from the COPD cohort were correlated with the acoustic 
variables from the COPD cohort, the following significant relationship was observed:  the 
post-FEV1/FVC values significantly correlated with the COPD cohort inhale exhale 
ratios in the supine breathing task post albuterol, (r = 0.51, p = 0.03). 
There was no significant difference between the means in the asthma group and 
the means in the COPD group across all variables. It cannot be suggested that there are 
significant differences in acoustic characteristics derived from device algorithms that 





Figure 3. Pearson’s R Correlation Between The Asthmatic FVC And The Asthmatic 






Figure 4. Pearson’s R Correlation Between The Asthmatic FEV1/FVC Ratio And 
The Asthmatic Inhale Exhale Ratio During Tidal Breathing Task Post Albuterol. 





Figure 5. Pearson’s R Correlation Between The COPD FEV1/FVC Ratio And The 
COPD Inhale Exhale Ratio During Supine Breathing Task Breathing Post 




There were thirteen subjects who had both a diagnosis of COPD and asthma. 
These subjects defined as those who had Asthma COPD Overlap Syndrome (ACOS) as 
they met both the diagnostic criteria for asthma and COPD as described in the inclusion 
criteria (Figure 6).  The demographic data is shown in Table 6. Overall, the majority of 
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ACOS subjects were previous smokers with significantly high average blood eosinophil 
levels.  
Taking a deeper look into the eosinophil levels, of the subjects who met the 
ACOS group criteria, only four of thirteen (31%) showed elevated absolute eosinophil 
counts (Table 5). What can be observed is that there were a great number of asthma 
subjects with elevated eosinophils counts.  
The PFT values of the ACOS subjects are showed in Table 8. Of the thirteen 
subjects with defined ACOS only two had a significant bronchodilator response with the 
overall average change in FEV1 and FVC not meeting the criteria for a significant 
bronchodilator response.  
 
 





Table 5. Demographics, Social and Clinical Characteristics of ACOS Study 
Participants. 
 









Race   
White American 18 
Black or African 
American 
6 
 Asian American 1 
Some other race 1 
Unavailable/Unknown 1 
Smoking Status  
Never Smoker 1 
Previous Smoker (QUIT) 11 
Current Smoker 1 
>20 pack years 11 
Race   
White American 10 
Black or African 
American 
3 
Blood Eosinophil Count  
Absolute (K/uL)  0.64 







Table 6. Blood Eosinophil Levels in ACOS Patients. Mild  = FEV1 % predicted >70; 
moderate = FEV1 % predicted 60-69; moderately severe = FEV1 % predicted 50-59; 





Absolute (K/uL) Percent (%) 
Mild (n=2) 0.34 3.55 




Severe (n=3) 1.08 11.43 
Very Severe (n=4) 0.31 3.35 
Total 0.64 6.87 
 
 
Table 7. Summary PFT Measurements for ACOS Study Participants. 
 ACOS (n=13) 
PFT  
Pre-FEV1 (Liters) 1.16 
Pre-FEV1 (% predicted) 47.54 
Post-FEV1 (Liters) 1.29 
Post-FEV1 (% predicted) 52.55 
Pre-FVC (Liters) 2.21 
Pre-FVC (% predicted) 69.92 
Post-FVC (Liters) 2.38 
Post-FVC (% Predicted) 74.55 
Pre-FEV1/FVC (Liters) 53.31 
Post-FEV1/FVC (Liters) 54.18 
Change in FEV1 (Liters) 0.12 
Change in FVC (Liters) 0.14 






Analyzing acoustic characteristics could develop into the new tool needed for 
immediate and accurate diagnosis, efficient treatment, and increase patient adherence. 
Many patients may not have the time nor the resources to receive care. It is also very 
common that patients with debilitating diseases have difficulty adhering to medication 
and rehabilitation regimens. Additionally, patients might have to wait months to get a 
clinical diagnosis and treatment.  
This paper investigates a novel biomarker to characterize patients with asthma 
and COPD by analyzing the following acoustic variables: pause time, pause frequency, 
respiration rate, and inhale exhale ratio. In this preliminary research study, we found that 
the inhale:exhale ratio and pause frequency had significant correlation with lung function 
in patients with obstructive lung disease. This indicates there are significant changes in 
speech due to the irregular airflow in patients with chronic inflammation or airway 
obstruction seen in COPD and asthma. As a result, acoustic biomarkers can illustrate 
compromised pulmonary function, as demonstrated by a hospital administered spirometry 
test.  
It cannot be confirmed that there is a difference in acoustic characteristics 
between patients with COPD and patients with asthma because there was a lack of 
difference between the means in the asthma group and the means in the COPD group 
across all variables. It is likely due to the limited sample size of the cohorts; smaller 
samples have higher variability, therefore it is harder to prove that a difference is due to a 




There were several limitations to this study. First, the sample size for each cohort 
was small.  A small sample size shows higher variability in data, this affects the 
reliability of the results. Secondly, in order to have a more accurate spirometry, subjects 
must withhold asthma or COPD medication in order to best assess airway reversibility. In 
this study, it was not determined whether the subject withheld their medication the day 
the bronchodilator test was performed. This could have had implications in the accuracy 
of the lung function values.  
FUTURE DIRECTION 
Current research is using several speech, respiratory, and cough features that are 
measured with wearable technology and analyzed for features using voice analytic 
algorithms. In this study, four acoustic variables were used to analyze data: pause time, 
pause frequency, respiratory rate and inhale exhale. Other acoustic biomarkers could 
unfold when studying significant changes in lung function longitudinally or before an 
exacerbation.  Analysis on cough frequency and characteristics should also be assessed 
since many of the patients seen in this study had distinct coughs.  
 More research needs to be conducted using vocal analytics that can annotate an 
audio source with greater diversity and specificity. Additionally, vocal analytics should 




Lastly, more investigation into ACOS patients is needed to better define this 
relatively new diagnosis. This initiative could lead to precision medicine, provide 
symptom monitoring, and aid physicians in assessment and management of disease.  
CONCLUSION 
The current tools that physicians use to diagnose and treat asthma and COPD can 
lack in specificity and sensitivity. This study has described a novel approach to 
characterize asthma and COPD by using acoustic variables, which can be a tremendous 
advancement in health care. Recording speech allows patients to assess pulmonary health 
without the burden of commuting to the hospital for an evaluation. Advancement in 
medical devices that monitor continuous health data can also improve a physician’s 
diagnosis of severity and variability of a patient’s symptoms. It can allow for an 
immediate evaluation and a change in medication, if needed. This quick assessment and 
continuous monitoring could increase patient adherence especially to those that may not 
have the time nor resources to receive care. The hope of this paper is to pave an avenue 
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